AlphaCore Pharma Reports Positive Phase 1 Results for ACP-501 (rhLCAT) in Patients With Stable Atherosclerosis

Published: Oct 09, 2012

ANN ARBOR, Mich.--(BUSINESS WIRE)--AlphaCore Pharma, announced today that results from the company’s Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the drug ACP-501 (recombinant human LCAT).

Back to news